DaShenLin Pharmaceutical Group Dividends and Buybacks
Dividend criteria checks 4/6
DaShenLin Pharmaceutical Group is a dividend paying company with a current yield of 4.36% that is well covered by earnings.
Key information
4.4%
Dividend yield
0.006%
Buyback Yield
| Total Shareholder Yield | 4.4% |
| Future Dividend Yield | 3.4% |
| Dividend Growth | 25.8% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | CN¥0.620 |
| Payout ratio | 83% |
Recent dividend and buyback updates
No updates
Recent updates
Take Care Before Diving Into The Deep End On DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233)
Sep 30
DaShenLin Pharmaceutical Group Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models
Sep 03DaShenLin Pharmaceutical Group (SHSE:603233) May Have Issues Allocating Its Capital
Aug 20Not Many Are Piling Into DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) Stock Yet As It Plummets 27%
Jun 17Does DaShenLin Pharmaceutical Group (SHSE:603233) Have A Healthy Balance Sheet?
Jun 09Are Investors Undervaluing DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) By 30%?
May 21Some May Be Optimistic About DaShenLin Pharmaceutical Group's (SHSE:603233) Earnings
May 06Investors Could Be Concerned With DaShenLin Pharmaceutical Group's (SHSE:603233) Returns On Capital
Apr 09Lacklustre Performance Is Driving DaShenLin Pharmaceutical Group Co., Ltd.'s (SHSE:603233) Low P/E
Mar 17Stability and Growth of Payments
Fetching dividends data
Stable Dividend: 603233 has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: 603233's dividend payments have increased, but the company has only paid a dividend for 7 years.
Dividend Yield vs Market
| DaShenLin Pharmaceutical Group Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (603233) | 4.4% |
| Market Bottom 25% (CN) | 0.6% |
| Market Top 25% (CN) | 2.2% |
| Industry Average (Consumer Retailing) | 2.0% |
| Analyst forecast (603233) (up to 3 years) | 3.4% |
Notable Dividend: 603233's dividend (4.36%) is higher than the bottom 25% of dividend payers in the CN market (0.59%).
High Dividend: 603233's dividend (4.36%) is in the top 25% of dividend payers in the CN market (2.24%)
Earnings Payout to Shareholders
Earnings Coverage: At its current payout ratio (82.8%), 603233's payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonably low cash payout ratio (47.5%), 603233's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/08 17:59 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
DaShenLin Pharmaceutical Group Co., Ltd. is covered by 18 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shaoling Wang | Chasing Securities |
| Qianyi Li | China International Capital Corporation Limited |
| Mujun Shen | Citic Securities Co., Ltd. |